현재 위치
Home
Medical / Pharmaceutical Biotechnology Symposium : 좌장 : 이지원 교수(고려대학교)
Targeting Signal Transduction pathways: Protein Kinases & Oncology, Perfect Together!
-
- 발행기관
- 한국생물공학회 바로가기
-
- 간행물
- 한국생물공학회 학술대회 바로가기
-
- 통권
- 2009 추계학술대회 및 국제심포지움 (2009.11)바로가기
-
- 페이지
- pp.92-92
-
- 저자
-
- 언어
- 영어(ENG)
-
- URL
- https://www.earticle.net/Article/A114456
※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.
원문정보
초록
- 영어
- There can be no doubt that oncology drug development is entering a critical phase. This phase is driven by the ever expanding knowledge of genomics and proteomics, breakthrough advances in drug discovery/drug design, and new in vitro and in vivo testing methodologies that allow drugs faster entry into clinical trials. The industry is on the brink of introducing a range of targeted therapeutics that promise to revolutionise cancer treatment. However, developing Oncology products is full of major challenges that need to be met head on in order to bring safe and effective treatments to market. Kinases are perhaps the most druggable class of targets, and yet researchers have only begun to scratch the surface. The ubiquity of kinases as potential targets means that eventually they will be exploited for virtually every human disease, particularly diabetes, inflammatory disorders, and especially cancer. The success of Novartis' Gleevec, Roche's Herceptin, AsraZeneca’s Iressa and OSI’s Tarceva has demonstrated that kinase inhibitors for cancer that are effective and well-tolerated. However, these successful drugs are just the top of an emerging line of therapy. Nonetheless, challenges remain, including: ensuring target relevance and specificity, overcoming resistance. There are today more than 245 protein kinase inhibitors for the treatment of cancer, from early preclinical to marketed drugs. Developmental stage contains more than 245 PKI drugs in development or more than 450 clinical projects for cancer:
> 25 projects in Phase III
> 160 projects in Phase II
> 110 projects in Phase I
> 180 projects in Preclinical
The Oncology market is currently valued at $34 billion/year and is set to top $55 billion in 2009. It is no surprise that big pharma is investing up to 20% of its annual R&D budget on the development of cancer treatment. Given the fact that they all target kinases and that kinase mutations can cause patients to become resistant to these drugs, there is plenty of room for more competition. Since virtually all the big pharmas have kinase R&D programs ongoing, we need to stay on top of the R&D and commercial developments in the area of kinase therapeutics.
저자
간행물 정보
발행기관
-
- 발행기관명
- 한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
- 설립연도
- 1984
- 분야
- 공학>생물공학
- 소개
- 이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다 1. 생물공학 분야의 발전을 위한 연구 협력 2. 생물공학의 실용화를 촉진시키기 위한 산학 협동 3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최 4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간 5. 생물공학 발전을 위한 정책 건의 6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동
간행물
-
- 간행물명
- 한국생물공학회 학술대회
- 간기
- 반년간
- 수록기간
- 1985~2013
- 십진분류
- KDC 476 DDC 576
이 권호 내 다른 논문 / 한국생물공학회 학술대회 2009 추계학술대회 및 국제심포지움
피인용수 : 0건 (자료제공 : 네이버학술정보)
함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.
출처 : 네이버학술정보
0개의 논문이 장바구니에 담겼습니다.